What are the indications for intrapleural chemotherapy (lung bath) in a child with Wilms tumor and pulmonary metastases?

Lung Bath (Intrapleural Chemotherapy) is NOT a Standard Indication in Wilms Tumor with Lung Metastases

Based on the most current NCCN Guidelines (Version 2.2025), there is no indication for intrapleural chemotherapy ("lung bath") in the management of Wilms tumor with pulmonary metastases. 1

Standard Treatment for Lung Metastases in Wilms Tumor

The established approach for pulmonary metastases in Wilms tumor consists of:

Systemic Chemotherapy

• Initial treatment: DD4A regimen (vincristine/dactinomycin/doxorubicin) for 6 weeks 1
• Risk-stratified intensification: Patients with incomplete response (IR) or loss of heterozygosity at 1p/16q receive Regimen M (adding cyclophosphamide/etoposide to DD4A) 1

Whole Lung Radiation Therapy (WLI)

• Indicated for: Stage IV disease with lung metastases that show incomplete response after initial chemotherapy 1
• Can be omitted: In patients achieving complete lung nodule response (CR) after 6 weeks of DD4A, though this carries slightly higher relapse risk 2
• Timing consideration: Should be coordinated with abdominal radiation planning to minimize overlapping fields 1

Surgical Resection of Pulmonary Metastases

• Reserved for: Post-chemotherapy pulmonary oligometastases when feasible, particularly if protocols allow omission of whole-lung irradiation in select cases 3
• Not routine: Surgical removal is not standard first-line therapy but may be considered for residual disease after chemotherapy 4

Why Intrapleural Chemotherapy is Not Used

The NCCN guidelines make no mention of intrapleural chemotherapy across all treatment algorithms for Wilms tumor with lung metastases. The evidence base demonstrates:

• Systemic therapy is effective: The AREN0533 study showed 4-year overall survival of 95.6% using systemic chemotherapy with risk-stratified WLI 2
• Complete response achievable: 133 of 292 patients (45.5%) achieved complete lung nodule response with systemic DD4A alone 2
• Radiation addresses local control: WLI reduces lung relapse risk from 23.3% to 8.3% when indicated 5

Critical Treatment Principles

For Stage IV Wilms tumor with lung metastases:

1. Start with DD4A chemotherapy for 6 weeks
2. Re-image at week 6 to assess lung nodule response
3. Complete response (CR): Continue DD4A without lung radiation (though slightly higher relapse risk)
4. Incomplete response (IR) or 1p/16q LOH: Add Regimen M (cyclophosphamide/etoposide) plus whole lung irradiation 1, 2
5. Radiation timing: Administer within 10-14 days after nephrectomy, with coordinated planning for abdominal and lung fields 1

Common Pitfalls to Avoid

• Do not perform upfront biopsy of typical Wilms tumor before chemotherapy 1
• Do not delay radiation beyond 14 days post-surgery when indicated 1
• Do not use CT-only nodules as sole indication for intensified therapy without considering complete clinical picture 6
• Do not omit lung radiation in incomplete responders—this increases relapse risk nearly threefold 5

Outcome Data Supporting Standard Approach

The AREN0533 study demonstrated superior outcomes compared to historical controls:

• 4-year EFS: 85.4% (vs. 72.5% in NWTS-5)
• 4-year OS: 95.6% (vs. 84.0% in NWTS-5)
• CR group without radiation: 79.5% EFS, 96.1% OS
• IR group with intensified therapy: 88.5% EFS, 95.4% OS 2

The evidence unequivocally supports systemic chemotherapy with risk-stratified whole lung radiation as the standard of care—intrapleural chemotherapy has no role in current Wilms tumor management.